melanotan
Recent Rosacea Blog Posts

Clinuvel have announced that their treatment known as SCENESSE (yes another product insisting on all caps) has been approved as a treatment for Erythropoietic Protoporphyria (EPP) in Europe. SCENESSE has previously been granted Orphan Drug Designation in Europe, USA, Australia and Switzerland. Scenesse was approved for use in Italy in 2010. Europe approves novel Australian […]

News today that Scenesse has progressed another step towards wider approval with the commencement of Phase III Trials. About 100 people with the condition Erythropoietic Protoporphyria (EPP) will be double blinded to receive the Scenesse implant or placebo. Their ability to tolerate sunlight will then be measured. The trials will take place in Alabama, California, […]

Clinuvel has announced today that Italy has pre-empted the approval of Afamelanotide by the FDA in the US by approving it for the treatment of erythropoietic protoporphyria (EPP). Despite the relatively small number of participants in the Italian trial to treat EPP, and the small number of EPP sufferers thought to directly benefit from this […]
There is a lot of interest amongst rosacea sufferers surrounding the possibility of some kind of systemic treatment that will offer better UV protection. Especially for those with severe triggers from sun exposure, treatments like Afamelanotide look promising. The CEO and Director of Clinuvel, Dr Philippe Wolgen, was kind enough to answer some questions relating […]
A blog posting at Clinuvel interviews a family struggling with the severe disease Erythropoietic Protoporphyria. Parents Wendy and Ralph talk about the distress and anguish at seeing their young children suffer the pain of EPP. Also known as absolution light intolerance, Erythropoietic Protoporphyria (EPP) is caused by a build up of protoporphyrin in the skin. […]